Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aurinia Pharmaceuticals Inc.
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Written informed consent
Healthy male or female subjects aged \>=18 and \<=55 years
Body mass index \>=18.0 and \<32 kg/m2
You may not be if
Abnormal ECG and/or prolonged QT interval
Subjects using nicotine products within 3 months prior to screening
Subjects who have lost or donated \>450 mL of whole blood or blood products within 30 days prior to the Screening Visit.
Use of any prescription medication within 14 days prior to the first dose of study medication, or any over-the-counter products (including natural health products, e.g., food supplements, vitamins, herbal supplements) within 7 days prior to the first dose of study medication, except for topical products without significant systemic absorption.
Use of any drugs or substances known to induce or inhibit hepatic drug metabolism within 28 days prior to administration of the study medication
Consumption of grapefruit or grapefruit juice, pomelo or star fruit within 7 days of first dose of study drug on Day 1
Use of hormonal contraception or hormone replacement therapy within 14 days prior to first dose of study drug.
No COVID-19 vaccines are allowed within 28 days prior to first dose of study drug.
History of or current alcohol abuse or drug addiction
Subjects who are pregnant or breast feeding
Subjects who have received any investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to screening.
Subjects who have any significant health issues as deemed by their treating physician/investigator
Clareo Health | Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin
